P-tau181 Biomarker Predicts Risk of Alzheimer Dementia
Plasma phosphorylated tau181 (P-tau181) may aid in the diagnosis of Alzheimer disease (AD), a study in Natural Medicine suggests.
Alzheimer Disease
Nonpharmacologic Interventions Reduce Agitation in Dementia
Nonpharmacologic more efficacious than pharmacologic interventions for reducing aggression, agitation.
Leveraging Neuroimaging for the Diagnosis of Psychiatric and Neurodegenerative Diseases
A number of psychiatric and neurodegenerative diseases are associated with abnormal imaging findings, which can help psychiatrists reach a diagnosis.
Physical Frailty Associated With Symptoms of Dementia, Caregiver Burden in Alzheimer Disease
Per study data published in the Journal of Clinical Psychiatry, investigators hypothesized that the correlation between higher Frailty Index scores and increased caregiver burden was partially mediated by increased behavioral and psychological symptoms of dementia.
Cortisol Levels May Contribute to Global Cognitive Decline in Elderly Adults With Depression
These data indicate that cortisol levels may contribute to the cognitive decline observed in elderly adults with late-life depression.
Increased Levels of Human Herpesvirus Identified in Alzheimer Disease
Participants with Alzheimer disease have increased levels of 2 strains of human herpesvirus.
Sugary Drinks, Other Added Sugars May Up Risk for Alzheimer Disease
Drinking sugary beverages has been previously linked to markers of preclinical Alzheimer disease, but the risk associated with consuming added sugars is not established.
Cannabinoid Shows Promise for Reducing Agitation, Aggression in Alzheimer Disease
Although treatment with nabilone significantly improved agitation, cognition, and nutrition, the authors cautioned that sedation should be closely monitored.
Intensive Blood Pressure Control Cuts Combined Mild Cognitive Impairment, Dementia Risk
In the previous SPRINT study, researchers compared an intensive BP reduction strategy (target systolic BP <120 mmHg) vs standard BP reduction strategy (target systolic BP <140 mmHg).
Details of Montreal Cognitive Assessment Widely Publicized After President Donald Trump’s Evaluation
Many published news articles included details of the Montreal Cognitive Assessment (MoCA) in association with President Trump, some of which invited readers to self-administer the test.
Next post in Neurocognitive Disorders
